BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...Inc. hired Marella Thorell as CFO. She was CFO, COO and an executive director of Realm Therapeutics plc...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...Palladio Biosciences Inc. (Newtown, Pa.) hired Alex Martin as CEO. He was previously CEO of Realm Therapeutics plc...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...Nuvelution Pharma Inc. (Cambridge, Mass.) and board member of Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) and Realm Therapeutics plc...
BioCentury | Aug 17, 2018
Clinical News

Realm's atopic dermatitis candidate misses in Phase II

...indication in 1Q19. Realm said it will provide an update on its plans next month. Realm Therapeutics plc...
...and pruritus Numerical Rating Scale (NRS) scores Status: Preliminary Phase II data Milestone: NA Jaime De Leon PR022 Realm Therapeutics plc...
BioCentury | Mar 16, 2018
Clinical News

Realm discontinues development of allergic conjunctivitis candidate

...redness as measured by the Ora Calibra Ocular Hyperemia Scale on days seven to eight. Realm Therapeutics plc...
...Calibra Ocular Hyperemia Scale on days seven to eight Status: Development discontinued Milestone: NA Jaime De Leon PR013 Realm Therapeutics plc...
BioCentury | Dec 8, 2017
Clinical News

Realm begins Phase II trial of PR022 for atopic dermatitis

...scores. PR022 is a topical gel formulation containing a high dose concentration of hypochlorous acid. Realm Therapeutics plc...
...pruritus Numerical Rating Scale (NRS) scores Status: Phase II started Milestone: Phase II data (3Q18) Allison Johnson PR022 Realm Therapeutics plc...
BioCentury | Sep 22, 2017
Financial News

Realm raises L19.3M

...On Sept. 21, dermatology and ophthalmology company Realm Therapeutics plc (LSE:RLM) raised £19.3 million ($26.2 million) through the...
...solution formulations, respectively, containing a high concentration of hypochlorous acid. Realm Therapeutics plc (LSE:RLM), Malvern, Pa. Elizabeth S. Eaton PR013 PR022 Realm Therapeutics plc...
BioCentury | Sep 21, 2017
Financial News

Realm raises £19.3M

...Dermatology and ophthalmology company Realm Therapeutics plc (LSE:RLM) raised £19.3 million ($26.2 million) through the sale of 66.4...
...containing a high concentration of hypochlorous acid. Realm was unchanged at 29.50p on Thursday. Elizabeth S. Eaton PR013 PR022 Realm Therapeutics plc...
BioCentury | Mar 11, 2013
Company News

PreCision Dermatology, PuriCore deal

...dermatology subsidiary Onset Dermatologics to develop and manufacture a dermatologic hydrogel to treat atopic dermatitis. PuriCore...
...product, which Onset will exclusively market and distribute in the U.S. as Aurstat Anti-Itch Hydrogel. PuriCore...
...of its Vashe technology. The 510(k) clearance triggered an undisclosed milestone to PuriCore from Onset. PuriCore...
BioCentury | Jul 25, 2011
Company News

Insmed management update

...Drucker as SVP, general counsel and corporate secretary, formerly SVP, general counsel and secretary at PuriCore...
Items per page:
1 - 10 of 11
BioCentury | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

...Inc. hired Marella Thorell as CFO. She was CFO, COO and an executive director of Realm Therapeutics plc...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...Palladio Biosciences Inc. (Newtown, Pa.) hired Alex Martin as CEO. He was previously CEO of Realm Therapeutics plc...
BioCentury | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

...Nuvelution Pharma Inc. (Cambridge, Mass.) and board member of Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) and Realm Therapeutics plc...
BioCentury | Aug 17, 2018
Clinical News

Realm's atopic dermatitis candidate misses in Phase II

...indication in 1Q19. Realm said it will provide an update on its plans next month. Realm Therapeutics plc...
...and pruritus Numerical Rating Scale (NRS) scores Status: Preliminary Phase II data Milestone: NA Jaime De Leon PR022 Realm Therapeutics plc...
BioCentury | Mar 16, 2018
Clinical News

Realm discontinues development of allergic conjunctivitis candidate

...redness as measured by the Ora Calibra Ocular Hyperemia Scale on days seven to eight. Realm Therapeutics plc...
...Calibra Ocular Hyperemia Scale on days seven to eight Status: Development discontinued Milestone: NA Jaime De Leon PR013 Realm Therapeutics plc...
BioCentury | Dec 8, 2017
Clinical News

Realm begins Phase II trial of PR022 for atopic dermatitis

...scores. PR022 is a topical gel formulation containing a high dose concentration of hypochlorous acid. Realm Therapeutics plc...
...pruritus Numerical Rating Scale (NRS) scores Status: Phase II started Milestone: Phase II data (3Q18) Allison Johnson PR022 Realm Therapeutics plc...
BioCentury | Sep 22, 2017
Financial News

Realm raises L19.3M

...On Sept. 21, dermatology and ophthalmology company Realm Therapeutics plc (LSE:RLM) raised £19.3 million ($26.2 million) through the...
...solution formulations, respectively, containing a high concentration of hypochlorous acid. Realm Therapeutics plc (LSE:RLM), Malvern, Pa. Elizabeth S. Eaton PR013 PR022 Realm Therapeutics plc...
BioCentury | Sep 21, 2017
Financial News

Realm raises £19.3M

...Dermatology and ophthalmology company Realm Therapeutics plc (LSE:RLM) raised £19.3 million ($26.2 million) through the sale of 66.4...
...containing a high concentration of hypochlorous acid. Realm was unchanged at 29.50p on Thursday. Elizabeth S. Eaton PR013 PR022 Realm Therapeutics plc...
BioCentury | Mar 11, 2013
Company News

PreCision Dermatology, PuriCore deal

...dermatology subsidiary Onset Dermatologics to develop and manufacture a dermatologic hydrogel to treat atopic dermatitis. PuriCore...
...product, which Onset will exclusively market and distribute in the U.S. as Aurstat Anti-Itch Hydrogel. PuriCore...
...of its Vashe technology. The 510(k) clearance triggered an undisclosed milestone to PuriCore from Onset. PuriCore...
BioCentury | Jul 25, 2011
Company News

Insmed management update

...Drucker as SVP, general counsel and corporate secretary, formerly SVP, general counsel and secretary at PuriCore...
Items per page:
1 - 10 of 11